Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Acorda Therapeutics
• Treatments: 4-Aminopyridine

Criteria

Inclusion Criteria:

• Patient with clinically defined multiple sclerosis

• All patients must be able to complete two trials of a timed 25 foot walk

Exclusion Criteria:

• Female patients who are either pregnant or breastfeeding.